Laurus Labs Investor Relations Material
Latest events
Q1 25/26
Laurus Labs
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Laurus Labs Ltd
Access all reports
Laurus Labs Limited, a pharmaceutical company, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and formulations in India. It involves in the development of antiviral APIs; generic APIs for hepatitis C and HIV Darunavir tablets; and oncology BCS class II drugs. The company also develops and commercializes single super specialty products comprising linezolid and formoterol. The company was incorporated in 2005 and is based in Hyderabad, India.
Key slides for Laurus Labs Ltd
Q4 2025
Laurus Labs Ltd
Q2 24/25
Laurus Labs Ltd
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
LAURUSLABS
Country
🇮🇳 India